Sequence evolution of the hypervariable region 1 (HVR1) in the N terminus of E2/NS1 of hepatitis C virus (HCV) was studied retrospectively in six chimpanzees inoculated with the same genotype 1b strain, containing a unique predominant HVR1 sequence. Immediately after inoculation, all animals contained the same HVR predominant sequence. Two animals developed an acute self-limiting infection. Anti-HVR1 immunoglobulin G (IgG) was produced 40 to 60 days after inoculation and rapidly disappeared after normalization of transaminases. Another chimpanzee, previously infected with human immunodeficiency virus type 1, showed a delayed response to HVR1 epitopes after superinfection with HCV. No sequence variation of HVR1 was observed in these two animals during the transient viremia in the acute phase. Three other chimpanzees developed a chronic HCV infection. During follow up, sequence evolution occurred in two animals and their anti-HVR1 response remained at varying but detectable levels. The first mutations occurred immediately after the production of anti-HVR1 during the acute phase. However, IgM anti-HVR1 was not detectable. Remarkably, HVR1 sequences remained conserved for more than 6 years in another chronically infected animal. This correlated with the complete absence of detectable anti-HVR1 during this period. Seven years after inoculation, anti-HVR1 IgG was produced and coincided with an HVR1 alteration. These results strongly suggest the involvement of neutralizing anti-HVR antibodies in sequence evolution of HVR1 through immune selection.
Hepatitis C virus (HCV) is associated with the majority of posttransfusion and sporadic viral hepatitis cases. The virus, classified as a relative of the flavi-and pestiviruses, possesses a positive-sense, single-stranded RNA genome of approximately 9,400 nucleotides (6, 7) . Besides 5Ј and 3Ј untranslated regions, the viral genome encodes a capsid protein (C), two putative envelope proteins (E1 and E2/NS1), and four nonstructural proteins (NS2 to NS5). NS5 encodes the putative RNA-dependent RNA polymerase.
Analysis of numerous HCV isolates revealed significant sequence heterogeneity among different viral isolates and resulted in the identification of at least six major genotypes and several subtypes (24) . Sequence variation is not evenly distributed along the viral genome. The 5Ј untranslated region is highly conserved and is therefore generally used as a target for diagnosis of viremia by PCR. The core, E1, and NS5 regions are more heterogeneous (1, 24, 25) . The most variable region was identified in the N terminus of the E2/NS1 region (13, 29) . This hypervariable region (HVR1) of approximately 27 amino acids (residues 384 to 410) has been shown to be highly variable among and within different patients (13, 17, 29, 30) . HVR1 can be used to identify individual HCV isolates, which is of particular interest for epidemiological studies (32) .
Sequence variation in HVR1 has been observed during chronic HCV infections in humans (9, 12, 16) and chimpanzees (22, 28) and appears to be comparable to that observed in the human immunodeficiency virus type 1 (HIV-1) gp120 V3 domain (31) . Furthermore, the HVR1 domain appears to be structurally flexible and contains linear B-cell epitopes that are well exposed at the outside of the virus and probably subjected to immune selection (18, 19, 23, 26, 31) . According to the immune selection hypothesis, neutralizing antibodies to HVR1 epitopes cause positive selection of escape mutants, which may play a role in the mechanism of persistent viral infection (23, 31) . Moreover, sequence variation of HVR1 may have important clinical implications, such as the efficacy of interferon treatment (21) .
We investigated the relationship between sequence evolution of HVR1 of a single well-defined HCV type 1b inoculum and the humoral immune response to the corresponding epitopes during acute and chronic infections in six chimpanzees.
MATERIALS AND METHODS
Chimpanzees. Experimental HCV infections in six chimpanzees (Phil, Peggy, Hans, Coen, Socrates, and Sophie) were performed between 1982 and 1987 and have been described in detail earlier (28) . Briefly, chimpanzees Phil, Peggy, and Hans were inoculated with different quantities of an HCV inoculum, derived from another chimpanzee (27) . Sequence analysis showed that this inoculum contained HCV genotype 1b. HCV was transferred from chimpanzee Phil to chimpanzees Socrates and Coen, and acute-phase plasma from Socrates was further passaged into chimpanzee Sophie. All chimpanzees were inoculated intravenously. Chimpanzees Phil, Peggy, and Hans developed a chronic infection, whereas Coen, Socrates, and Sophie experienced only acute infection. Coen had been previously infected with HIV-1. These HCV infections were initially monitored by measurements of alanine aminotransferase (ALT) and ␥-glutamyltransferase (g-GT) in serum.
Sequence analysis. Amplification primers and direct sequencing procedures have been described in detail elsewhere (28) . Briefly, HCV RNA was isolated from serum with the guanidinium thiocyanate-phenol method (4), reverse transcribed into cDNA, and subsequently amplified by nested PCR. One of the primers in the nested reaction was biotinylated, allowing preparation of singlestranded DNA suitable for direct sequencing of the PCR product (14) .
Anti-HVR1 antibody detection. Two overlapping biotinylated peptides covering the hypervariable region were synthesised on a Millipore 9050 PepSynthesizer. Peptide A (Bio-GSTYVTGGASGRSTHGLVSLF) covers amino acid residues 384 to 403, and peptide B (Bio-GRSTHGLVSLFNLGAQQKVQLINT) corresponds to residues 394 to 417. Peptides were dissolved in dimethyl sulfoxide, diluted with phosphate-buffered saline (PBS) to 10 mg/ml, and stored at Ϫ20ЊC. Dilutions of peptides were prepared in PBS with 5% glycerol.
An enzyme-linked immunosorbent assay (ELISA) was developed on the basis of biotinylated peptides A and B. Streptavidin (Boehringer, Mannheim, Germany) was coated onto 96-well Maxisorp plates (Nunc, Roskilde, Denmark) by incubating 200 ml (3 mg/ml) in each well for 1 h at 37ЊC.
Plates were washed three times with PBS, and 100 ml of the peptide solution (1 mg/ml) was added. Dilution experiments showed that 100 ng of peptide per well was sufficient to obtain an optimal signal. For each serum sample to be tested, duplicate wells were coated with either peptide A or B or without peptide for 1 h at 37ЊC. (Each serum sample requires six wells.) After three washes with PBS, the wells were blocked with PBSTG (PBS containing 0.05% Tween 20 and 0.5% gelatin) for 1 h at 37ЊC.
Serum samples were diluted 1:100 in PBSTG, and 100 ml was added to the wells and incubated for 1 h at 37ЊC. The wells were washed eight times with PBST (PBS with 0.5% Tween 20), and conjugate was added. Goat anti-human immunoglobulin G (IgG) peroxidase (produced at the Diagnostic Centre SSDZ) was appropriately diluted in PBSTG, added to the wells, and incubated at 37ЊC. After 1 h, the wells were washed eight times with PBST, and the substrate (3,3Ј,5,5Ј-tetramethylbenzidine [TMB]; Aldrich, Steinheim, Germany) was added. The reaction was stopped after 30 min by adding 100 ml of 3 N H 2 SO 4 -4 M urea. Color development was measured in a plate reader at 450 nm.
Mean optical densities from duplicate wells containing either peptide A or B were calculated, and the mean optical density of the control wells (no peptide) was subtracted. If the variation between two duplicate wells was higher than 10%, the samples were retested. Repeated samples gave consistent results in the same range, and large discrepancies between repeated samples were never observed. Serum samples from each chimpanzee were all processed on the same day, and each plate contained a positive control serum sample.
RESULTS
Sequence evolution of the hypervariable region HVR1 was studied retrospectively in six chimpanzees infected with a unique genotype 1b HCV isolate. HCV RNA was reverse transcribed into cDNA, amplified, and subjected to direct sequence analysis. HVR1 nucleotide and amino acid sequences are shown in Fig. 1 and 2 , respectively. At some positions, sequence ambiguity was observed, seen as double bands on the sequencing gel. The parental HVR1 variant, present in the source plasma, was present in all chimpanzees shortly after inoculation. For chimpanzees Coen, Socrates, and Sophie, which developed acute hepatitis, several serum samples throughout the acute phase were analyzed, and no sequence alterations were observed during the transient period of viremia.
From the chronically infected animals, multiple sequences were determined in samples obtained up to 10 years after infection. During the acute phase in Hans and Peggy, the parental consensus sequence of the inoculum rapidly changed and variants were observed within several months. HCV RNA from chimpanzee Peggy was analyzed at multiple times during the acute phase of infection. As shown in Fig. 1 and 2 , the parental sequence was detected until 62 days after infection. At 76 days after infection, a double band (C/T) appeared at position 1188, but this mutation is silent. At 92 days after infection, the first non-silent mutation (Leu-405 to Pro) was detected at position 1214, and at 125 days after infection, the second non-silent mutation (Val-411 to Ile) was detected at position 1231. Later during infection, additional mutations were detected. However, in chimpanzee Phil, no sequence alterations were detected between December 1982 and November 1989. In the 1991 isolate, a single amino acid alteration (Gln-409 to Leu) was observed. In the 1989 sample, sequence ambiguity suggested the possible presence of both Ile and Val at position 415.
Antibodies against linear HVR1 epitopes, presented as overlapping peptides A and B, were determined in serial serum samples from the six chimpanzees. Peptide sequences were based on the parental sequence as detected in the original inoculum and in each chimpanzee shortly after inoculation. Results are shown in Fig. 3 . Anti-peptide A antibody levels were lower than anti-peptide B levels in the majority of samples.
In chimpanzees Socrates and Sophie ( Fig. 3A and B ), showing acute self-limiting hepatitis, high levels of anti-HVR1 IgG antibodies were produced 40 to 60 days after inoculation, coinciding with the rise of both liver-specific enzymes ALT and g-GT. Anti-HVR1 IgG levels rapidly diminished after normalization of the serum ALT levels and dropped below the detection limit approximately 150 to 200 days after infection. In chimpanzee Coen (Fig. 3C) , low anti-HVR1 antibody levels became detectable 60 to 80 days after infection. Compared with those of the other animals, the antibody response seemed delayed, since it occurred after normalization rather than during elevation of liver enzymes. Eventually, the modest antibody levels decreased to just above the detection limit.
In chronically infected chimpanzees Peggy and Hans ( Fig.  3D and E) , high levels of anti-HVR1 antibodies also became rapidly detectable after inoculation, again coinciding with liver enzyme elevations. However, after normalization of these enzyme levels, fluctuating levels of anti-HVR1 remained present for prolonged periods.
Chimpanzee Phil did not develop antibodies against peptides A and B throughout the acute phase of the disease (Fig.  3F) . Low levels of anti-HVR1 antibodies were first detected in 1989, more than 6 years after inoculation.
DISCUSSION
The sequence evolution of the hypervariable region in the 5Ј terminus of E2/NS1 encoding one of the putative envelope proteins was studied in a well-characterized group of six chimpanzees infected with HCV.
RNA genomes have a relatively high mutation rate, because of errors of the RNA-dependent RNA polymerase during copying of the template RNA. An RNA virus population exists as a distribution of mutant genomes termed viral quasispecies, comprising coexisting mutant genomes with a consensus or master sequence (8, 12, 20) . If a specific mutant has a higher competitive fitness than the parental sequence, or if selective forces such as an immune response evolve, this can influence the distribution between different viral variants and will consequently cause a change in the consensus sequence. This two-step process of mutant generation followed by selection results in antigenic diversification of RNA viruses. The immune response is assumed to select variants directly, although alternative mechanisms may also contribute, e.g., selection of variants that interact better with cell receptors (8) .
Recently, Weiner and coworkers suggested that HVR1 domains of HCV are subjected to immune selection (31) . Antibodies against this presumably well-exposed epitope of the putative viral envelope protein (23, 26, 31) possibly neutralize a specific virus variant, resulting in the selection of escape mutants whose evolution is favored by a transient failure of the host immune system to neutralize the newly emerging variant. This escape mutant rapidly becomes predominant while the replication of the parental variant is efficiently inhibited. Different HVR1 sequences were detected during different episodes of chronic hepatitis, and alteration of the sequence was accompanied by the presence of specific antibodies to corresponding HVR1 peptides (31) .
We studied the relationship between sequence evolution of the hypervariable region and the humoral immune response to the corresponding epitopes in six chimpanzees that had been infected with an identical HCV inoculum (28) . The availability of many serial serum samples from these animals allowed the precise monitoring of sequence evolution and antibody formation. Sequences were determined by direct sequence analysis of PCR-amplified cDNA fragments, avoiding the possible sampling errors encountered by analysis of individual clones. Also, errors by reverse transcriptase and Taq DNA polymerase are unlikely to be detected. Direct sequence analysis allows detection of the master sequence and is particularly useful for measuring changes in this consensus sequence of a population of genomes. On the other hand, direct sequencing does not provide detailed information about minor variants in the population.
HVR1 sequence alterations were not detected during the transient viremia in acutely infected chimpanzees Socrates and Sophie, although humoral immune responses against HVR1 were rapidly detectable after inoculation, coinciding with elevated levels of ALT and g-GT. The period of viremia was probably too brief to allow the selection of escape mutants. By the time the anti-HVR1 antibodies reach a significant level, the viral RNA has already been cleared from the circulation (28) .
Chimpanzee Coen experienced an HCV infection with transient viremia. After normalization of ALT levels, HCV RNA was undetectable for at least 2 years (28). However, a single sample obtained 10 years after infection did contain detectable HCV RNA. Therefore, we conclude that chimpanzee Coen was also chronically infected. Unfortunately, additional samples were not available for HCV analysis. Because this animal had been previously infected with HIV-1, viral interference between HIV-1 and HCV (11) might be important. Remarkably, the anti-HVR1 antibody response in Coen clearly occurred after normalization of ALT and g-GT, whereas in other animals, it coincided with elevated levels of these enzymes, suggesting immunomodulatory effects of HIV-1.
Chimpanzee Peggy and Hans showed sequential alterations in the HVR1 region during chronic HCV infections. Most of the nucleotide alterations are replacement mutations. The putative conserved amino acids Thr-385, Gly-406, Gln-409, and Leu-413 (19) also remained conserved in these chimpanzees. The production of HVR1 specific antibodies and corresponding sequence alterations are in accordance with earlier reports (18, 19, 23) . Anti-HVR1 antibodies remained present at variable levels, which may be partly explained by cross-reactive anti-HVR1 antibodies, and suggest the continuing stimulation of the immune system with HVR1 epitopes. The rapid decrease in anti-HVR1 IgG in the acutely infected animals Sophie and Socrates was remarkable, since IgG responses to other viruses usually remain detectable during much longer periods. During the first vaccination experiments in chimpanzees (5), the levels of antibodies to E1 and E2 also rapidly declined after immunization with recombinant protein. This apparent absence of long-term humoral immune response against HCV envelope epitopes may be very important for the development of an effective vaccine. In chimpanzee Phil, chronic HCV infection without any detectable humoral immune response is associated with the complete absence of hypervariability of HVR1 epitopes for more than 6 years. Because of the absence of a specific immune response against HVR1 epitopes, there are no mutants that have a higher competitive fitness. The reason underlying this unresponsiveness of Phil remains unclear but could be associated with the histocompatibility (HLA) genotype. An alternative explanation might be that immunological escape is induced only by an effective initial antiviral immune response upon primary infection, as has been suggested for HIV-1 (33) . Chimpanzee Phil was inoculated with a very low dose of virus (28) . Viremia was first detected in Phil 32 days after infection, whereas in chimpanzees Socrates and Sophie HCV RNA was detectable within a week. Also, the overall anti-HCV response in Phil seemed inefficient during the acute phase of infection. Between 1989 and 1991, a single amino acid change (Gln to Leu at position 409) was observed. This can possibly be related to low levels of anti-HVR1 antibodies detected around 2,500 days after inoculation. At 2,527 days after infection, the parental sequence was still detected. Unfortunately, the number of available serum samples from this period is very limited. Although the coincidence between the two observations is remarkable, we have failed to identify the cause that triggered the production of anti-HVR1 and the subsequent selection of an escape mutant 7 years after inoculation.
Analysis of the acute-phase samples of chimpanzee Peggy showed that the first HVR1 mutant emerged immediately after the production of anti-HVR1 IgG. This suggests that sequence alterations in HVR1 are not the result of rapid viral adaptation to a new host but occur only after the development of a specific antibody response. The results for chimpanzee Phil also show that sequence variation and escape mutants in the HVR1 are not essential for the development of a chronic HCV infection. Also, the efficacy of the anti-HVR1 response seems unrelated to complete clearance of the virus. The exact mechanisms of acute resolving versus persistent HCV infection remain obscure.
The biological function of the HVR1 region remains unclear. It is uncertain whether sequence alterations in HVR1 are associated with long-term adaptation of the virus to a specific host with changes in cell tropism and viral entry, as has been described for the HIV-1 V3 region (2, 3, 10, 15) . It might be speculated that chronic HCV infection leads to a slow adaptation to the host, with increasing clinical symptoms, such as cirrhosis and eventually hepatocellular carcinoma. Randomly generated HVR1 mutants may not only be subjected to a rapidly acting immune selection mechanism, but antigenic variation could also be driven by adaptive fitness of the virus to the host.
In conclusion, our results provide strong evidence for an immune selection mechanism of HVR1 variants in HCV. However, antigenic variation of HVR1 is not obligatory for the development of a chronic HCV infection. Since anti-HVR1 antibodies are considered to be neutralizing, modulation of the immune responses against these epitopes may have important implications for vaccination strategies.
